Selecta, a USA- Massachusetts, based company has announced to develop immunotherapies for treating life-threatening allergies caused by food. SVP (synthetic vaccine particle) platform will be used to identify and develop a compound.
Nanoparticles will be developed with the help SVP technology, an immunotherapy platform developed by Selecta. These particles would help in balancing over response to specific antigens and thereby producing immune tolerance.
The license of the compound to be used in immunotherapy will be possessed by Sanofi, a french pharmaceutical giant. Also, Sanofi will have an option for two additional compounds for treating food allergies caused by specific aeroallergens or food. Atarax
Selecta, in return, will get an estimated $300m for one allergen indication of total three immunotherapy compounds.
Sanofi is pharmaceutical giant in immunology and vaccines. Selecta is happy by collaboration with Sanofi to develop commercial pharmaceutical products using its SVP technology.
A safe treatment with higher efficacy which targets specific antigen is needed to stop inappropriate immune reactions by body immune system. The treatment would be useful in development of other treatments for which immune response is problem such as lysosomal storage disease.
The SVP technology restores balance in body immune systems. It does that by developing tolerance in immune systems for specific antigens.
Although the focus of the co-operation is different from other co-operations between pharmaceutical companies and technology firm, the structure of the pact is somewhat similar i.e. to allows firm to access library of the compounds. This is the third such pact. Pacts between GSK and Chiromics, Novartis and MorphoSys are examples.
Nanoparticles will be developed with the help SVP technology, an immunotherapy platform developed by Selecta. These particles would help in balancing over response to specific antigens and thereby producing immune tolerance.
The license of the compound to be used in immunotherapy will be possessed by Sanofi, a french pharmaceutical giant. Also, Sanofi will have an option for two additional compounds for treating food allergies caused by specific aeroallergens or food. Atarax
Selecta, in return, will get an estimated $300m for one allergen indication of total three immunotherapy compounds.
Sanofi is pharmaceutical giant in immunology and vaccines. Selecta is happy by collaboration with Sanofi to develop commercial pharmaceutical products using its SVP technology.
A safe treatment with higher efficacy which targets specific antigen is needed to stop inappropriate immune reactions by body immune system. The treatment would be useful in development of other treatments for which immune response is problem such as lysosomal storage disease.
The SVP technology restores balance in body immune systems. It does that by developing tolerance in immune systems for specific antigens.
Although the focus of the co-operation is different from other co-operations between pharmaceutical companies and technology firm, the structure of the pact is somewhat similar i.e. to allows firm to access library of the compounds. This is the third such pact. Pacts between GSK and Chiromics, Novartis and MorphoSys are examples.
No comments:
Post a Comment